- Date2025-11-18
Publication of Review Result of the 8th Pharmaceutical Reimbursement Evaluation Committee of 2025
□ The Health Insurance Review and Assessment Service (HIRA, President: Kang Jung-Gu) announced the results of the 8th Drug Benefit Evaluation Committee deliberations held in 2025.
○ Deliberation Results on the Appropriateness of Reimbursement for the Requested Drug
|
Product |
Manufacturer |
Indications |
Deliberation Results |
|
Livmali Injection (Maralixibat Chloride), GC Pharma |
GC Pharma |
Treatment of cholestatic pruritus in patients with Alagille syndrome. |
Reimbursement deemed appropriate |
|
Isturisa Film-Coated Tablets 1.5 mg (Osilodrostat Phosphate) |
Recordati Korea Co., Ltd. |
Treatment of adult patients with Cushing’s disease who are ineligible for pituitary surgery or do not achieve sufficient effect after surgery. |
Reimbursement deemed appropriate |
○ 2025 Health Insurance Drug Reimbursement Re-evaluation Deliberation Results
|
Active Ingredient |
Indications |
Deliberation Results |
|
Olopatadine Hydrochloride |
(Oral) Allergic rhinitis, pruritus associated with skin disorders |
Reimbursement deemed appropriate |
|
(Ophthalmic) Allergic conjunctivitis | ||
|
(Nasal spray) Seasonal allergic rhinitis | ||
|
Clematidis radix, Trichosanthis Radix, Prunella vulgaris |
Symptom relief for osteoarthritis (degenerative joint disease) and rheumatoid arthritis |
Reimbursement deemed appropriate |
|
Bepotastine |
(Oral) Perennial allergic rhinitis, chronic urticaria, and pruritus associated with skin disorders (eczema, dermatitis, pruritus, and scabies) |
Reimbursement deemed appropriate |
|
(Ophthalmic) Treatment of itching due to allergic conjunctivitis | ||
|
Spherical Adsorptive Carbon |
Improvement of uremic symptoms in progressive chronic renal failure and delay of dialysis initiation |
Reimbursement is not appropriate 1) |
|
Mugwort Extract |
Improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) in: acute gastritis, chronic gastritis |
Reimbursement is not appropriate 1) |
|
L-Aspartate-L-Ornithine |
(Oral) Adjunct therapy for detoxification in severe liver disease (e.g., cirrhosis) |
Reimbursement deemed appropriate2) ※ Limited to hepatic encephalopathy |
|
(Injection 0.1 g/mL) Adjunct therapy for severe liver disease: hepatitis, post-hepatitis sequelae, cirrhosis ☆ Domestic clinical trials (MFDS clinical re-evaluation) in progress |
Reimbursement is not appropriate1) | |
|
(Injection 0.5 g/mL) Adjunct therapy for severe liver disease: hepatic encephalopathy (pre-coma and coma stages) |
Reimbursement deemed appropriate | |
|
Selglicotide |
Gastritis and duodenitis ☆ Domestic clinical trials (MFDS clinical re-evaluation) in progress |
Reimbursement is not appropriate 3) |
|
Chenodeoxycholic Acid–Ursodeoxycholic Acid Trihydrate Magnesium Salt |
1. Cholesterol gallstones (radiolucent gallstones), particularly in patients with normal gallbladder function; residual or recurrent stones after biliary surgery 2. Biliary dyspepsia ☆ Domestic clinical trial (MFDS clinical re-evaluation) in progress |
Reimbursement is not appropriate1) |
1) No clinical usefulness evidence
2) Clinical usefulness unclear, but cost-effective
3) Clinical usefulness unclear and not cost-effective
- For the eight active ingredients, pharmaceutical companies may submit an objection to HIRA within 30 days of receiving the results. Submitted objections will be reviewed again by the Drug Benefit Evaluation Committee.
|
※ In accordance with Article 11-2 of the “Regulations on Standards for National Health Insurance Benefits,” the President of the Health Insurance Review and Assessment Service (HIRA) evaluates the appropriateness of drug coverage through deliberation by the Drug Benefit Evaluation Committee. The detailed coverage scope of the drug may differ from its indications, and the final evaluation results may change in the event of changes to standard items, modifications, or withdrawal (cancellation) of the approved specifications of the requested drug, or other relevant circumstances.
※ In accordance with Article 13, Paragraph 4, Item 17 of the “Regulations on Standards for National Health Insurance Benefits,” the President of the Health Insurance Review and Assessment Service (HIRA) conducts re-evaluation of the appropriateness of National Health Insurance drug coverage through deliberation by the Drug Benefit Evaluation Committee. Following notification of the evaluation results related to the specific ingredient, the final evaluation results may change depending on the pharmaceutical company’s appeal assessment. |
